Şeyma Yıldız
Şeyma Yıldız has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Sami Bahçebaşı
Internal Medicine Department, Kayseri City Hospital, Kayseri, Turkey
3 shared publications - Hatice Kayış Topaloğlu
NOVEL Health Strategies, Chevy Chase, MD, USA
2 shared publications - Melih Kızıltepe
Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Erciyes University, Kayseri, Turkey
2 shared publications - Mesut Kılıç
Department of Internal Medicine , Kayseri City Hospital , Kayseri , Turkey
2 shared publications - Sibel Ata
Department of Internal Medicine , Kayseri City Hospital , Kayseri , Turkey
2 shared publications - Ulaş Serkan Topaloğlu
Department of Internal Medicine, Kayseri City Hospital, 38080 Kayseri, Türkiye
2 shared publications
Latest Publications
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 9933219
Comparison of HbA1c and OGTT Results in Obese and Morbidly Obese Patients: A Single‐Center Evaluation From an Obesity Clinic
Introduction: Obesity, particularly morbid obesity, is associated with significant metabolic alterations such as insulin resistance and compensatory hyperinsulinemia. These pathophysiological changes may influence the performance and interpretation of glycemic diagnostic tools, including the oral glucose tolerance test (OGTT) and glycated hemoglobin (HbA1c). This study is aimed at comparing the diagnostic profiles of OGTT and HbA1c across BMI categories, with a specific focus on morbid obesity and the potential role of elevated insulin levels in test discrepancies. Materials and Methods: This retrospective study included 1031 patients who were classified into nonobese, obese, and morbidly obese groups based on body mass index (BMI). All participants underwent assessment of glycemic status, lipid profile, and related metabolic parameters. Results: Of the study population, 86.8% were female. Based on BMI classification, 56.5% were obese, 35.8% morbidly obese, and 7.8% nonobese. The prevalence of dysglycemia (prediabetes + diabetes) was 43.1% according to HbA1c and 30.9% according to OGTT. Dysglycemia was significantly more frequent in the morbidly obese group by HbA1c ( p < 0.001), while OGTT showed no significant intergroup difference ( p = 0.117). The agreement between methods was low ( κ = 0.326). HbA1c, insulin, HOMA‐IR, CRP, and triglyceride levels increased with BMI. Insulin‐related parameters were higher among HbA1c‐defined dysglycemic individuals. Discussion: HbA1c may be more sensitive in identifying early metabolic disturbances, particularly during the compensatory phase involving hyperinsulinemia. Elevated insulin levels may attenuate glucose response during OGTT, potentially reducing its diagnostic sensitivity.
- 1 January 2025
- Published by Wiley in Journal of Diabetes Research
- Vol. 2025 (1) , 9933219
Open AccessComparison of HbA1c and OGTT Results in Obese and Morbidly Obese Patients: A Single‐Center Evaluation From an Obesity Clinic
Introduction: Obesity, particularly morbid obesity, is associated with significant metabolic alterations such as insulin resistance and compensatory hyperinsulinemia. These pathophysiological changes may influence the performance and interpretation of glycemic diagnostic tools, including the oral glucose tolerance test (OGTT) and glycated hemoglobin (HbA1c). This study is aimed at comparing the diagnostic profiles of OGTT and HbA1c across BMI categories, with a specific focus on morbid obesity and the potential role of elevated insulin levels in test discrepancies. Materials and Methods: This retrospective study included 1031 patients who were classified into nonobese, obese, and morbidly obese groups based on body mass index (BMI). All participants underwent assessment of glycemic status, lipid profile, and related metabolic parameters. Results: Of the study population, 86.8% were female. Based on BMI classification, 56.5% were obese, 35.8% morbidly obese, and 7.8% nonobese. The prevalence of dysglycemia (prediabetes + diabetes) was 43.1% according to HbA1c and 30.9% according to OGTT. Dysglycemia was significantly more frequent in the morbidly obese group by HbA1c ( p < 0.001), while OGTT showed no significant intergroup difference ( p = 0.117). The agreement between methods was low ( κ = 0.326). HbA1c, insulin, HOMA‐IR, CRP, and triglyceride levels increased with BMI. Insulin‐related parameters were higher among HbA1c‐defined dysglycemic individuals. Discussion: HbA1c may be more sensitive in identifying early metabolic disturbances, particularly during the compensatory phase involving hyperinsulinemia. Elevated insulin levels may attenuate glucose response during OGTT, potentially reducing its diagnostic sensitivity.
- Open Access
- 23 December 2020
- Published by Walter de Gruyter GmbH in Drug Metabolism and Drug Interactions
- Vol. 36 (2) , 129-134
Fear of Hypoglycemia in Adults with diabetes mellitus switching to Treatment with IDegAsp Co-formulation to Examine real-world setting: an observational study (The HATICE study)
Objectives: To evaluate the clinical results of insulin degludec/aspart (IDEgAsp) therapy and its effect on the fear of hypoglycemia. Methods: A prospective observational study has been conducted through surveys of 36 patients using insulin because of type 2 diabetes mellitus who initiated treatment with IDegAsp switching from other insulins. Patients, 18–75 years old, were recruited to the study, consecutively. Participants’ age, gender, height, weight, body mass index (BMI), daily insulin dose, glycated hemoglobin (HbA1c), hypoglycemia rate, hypoglycemia fear survey (HFS) were recorded at the beginning of the study. By the end of 12th month, data was re-measured and compared with each other. Results: HbA1c was declined by mean of −1.59% (95% CI −1.06 to −2.12, p1c, less injection administration, and decreased the fear of hypoglycemia in diabetics.
- 23 December 2020
- Published by Walter de Gruyter GmbH in Drug Metabolism and Drug Interactions
- Vol. 36 (2) , 129-134
Open AccessFear of Hypoglycemia in Adults with diabetes mellitus switching to Treatment with IDegAsp Co-formulation to Examine real-world setting: an observational study (The HATICE study)
Objectives: To evaluate the clinical results of insulin degludec/aspart (IDEgAsp) therapy and its effect on the fear of hypoglycemia. Methods: A prospective observational study has been conducted through surveys of 36 patients using insulin because of type 2 diabetes mellitus who initiated treatment with IDegAsp switching from other insulins. Patients, 18–75 years old, were recruited to the study, consecutively. Participants’ age, gender, height, weight, body mass index (BMI), daily insulin dose, glycated hemoglobin (HbA1c), hypoglycemia rate, hypoglycemia fear survey (HFS) were recorded at the beginning of the study. By the end of 12th month, data was re-measured and compared with each other. Results: HbA1c was declined by mean of −1.59% (95% CI −1.06 to −2.12, p1c, less injection administration, and decreased the fear of hypoglycemia in diabetics.
- Open Access
- 21 October 2020
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
- Vol. -1 (ahead-of-p)
Fear of hypoglycemia in adults with diabetes mellitus switching to treatment with IDegAsp co-formulation to examine real-world setting: an observational study (The HATICE study)
Objectives: To evaluate the clinical results of insulin degludec/aspart (IDEgAsp) therapy and its effect on the fear of hypoglycemia. Methods: A prospective observational study has been conducted through surveys of 36 patients using insulin because of type 2 diabetes mellitus who initiated treatment with IDegAsp switching from other insulins. Patients, 18–75 years old, were recruited to the study, consecutively. Participants’ age, gender, height, weight, body mass index (BMI), daily insulin dose, glycated hemoglobin (HbA1c), hypoglycemia rate, hypoglycemia fear survey (HFS) were recorded at the beginning of the study. By the end of 12th month, data was re-measured and compared with each other. Results: HbA1c was declined by mean of −1.59% (95% CI −1.06 to −2.12, p1c, less injection administration, and decreased the fear of hypoglycemia in diabetics.
- 21 October 2020
- Published by Walter de Gruyter GmbH in Drug Metabolism and Personalized Therapy
- Vol. -1 (ahead-of-p)
Open AccessFear of hypoglycemia in adults with diabetes mellitus switching to treatment with IDegAsp co-formulation to examine real-world setting: an observational study (The HATICE study)
Objectives: To evaluate the clinical results of insulin degludec/aspart (IDEgAsp) therapy and its effect on the fear of hypoglycemia. Methods: A prospective observational study has been conducted through surveys of 36 patients using insulin because of type 2 diabetes mellitus who initiated treatment with IDegAsp switching from other insulins. Patients, 18–75 years old, were recruited to the study, consecutively. Participants’ age, gender, height, weight, body mass index (BMI), daily insulin dose, glycated hemoglobin (HbA1c), hypoglycemia rate, hypoglycemia fear survey (HFS) were recorded at the beginning of the study. By the end of 12th month, data was re-measured and compared with each other. Results: HbA1c was declined by mean of −1.59% (95% CI −1.06 to −2.12, p1c, less injection administration, and decreased the fear of hypoglycemia in diabetics.